Background and purpose: Peripheral immune cell infiltration to the brain tissue at the perisurgical site can promote neuroinflammation after surgical brain injury (SBI). Slit2, an extracellular matrix protein, has been reported to reduce leukocyte migration. This study evaluated the effect of recombinant Slit2 and the role of its receptor roundabout1 (Robo1) and its downstream mediator Slit-Robo GTPase activating protein 1 (srGAP1)-Cdc42 on peripheral immune cell infiltration after SBI in a rat model. Methods: One hundred and fifty-three adult male Sprague-Dawley rats (280-350 g) were used. Partial resection of right frontal lobe was performed to induce SBI. Slit2 siRNA was administered by intracerebroventricular injection 24 h before SBI. Recombinant Slit2 was injected intraperitoneally 1 h before SBI. Recombinant Robo1 used as a decoy receptor was co-administered with recombinant Slit2. srGAP1 siRNA was administered by intracerebroventricular injection 24 h before SBI. Post-assessments included brain water content measurement, neurological tests, ELISA, Western blot, immunohistochemistry, and Cdc42 activity assay. Results: Endogenous Slit2 was increased after SBI. Robo1 was expressed by peripheral immune cells. Endogenous Slit2 knockdown worsened brain edema after SBI. Recombinant Slit2 administration reduced brain edema, neurological deficits, and pro-inflammatory cytokines after SBI. Recombinant Slit2 reduced peripheral immune cell markers cluster of differentiation 45 (CD45) and myeloperoxidase (MPO), as well as Cdc42 activity in the perisurgical brain tissue which was reversed by recombinant Robo1 co-administration and srGAP1 siRNA. Conclusions: Recombinant Slit2 improved outcomes by reducing neuroinflammation after SBI, possibly by decreasing peripheral immune cell infiltration to the perisurgical site through Robo1-srGAP1 mediated inhibition of Cdc42 activity. These results suggest that Slit2 may be beneficial to reduce SBI-induced neuroinflammation.
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Introduction
Surgical brain injury (SBI) is the inadvertent injury to brain tissue at the perisurgical site which occurs due to neurosurgical maneuvers such as incision, retraction, and electrocoagulation that can aggravate post-operative brain edema and neurological deficits (Jadhav et al., 2007a , Huang et al., 2014 . Major complications are encountered in 13-27% patients after intracranial surgeries (Bruder, 2002) . Measures to reduce neurosurgical complications are limited (Jadhav et al., 2007a) . Furthermore, routine therapy used against SBI including hyperosmolar agents and steroids can have unwanted adverse effects (Li et al., 2014 , Xu et al., 2014 . Therapeutic strategies that augment endogenous protective mechanisms would be a safe approach to reduce post-operative complications in neurosurgical patients.
Neuroinflammation is a major pathophysiological consequence after SBI (Yamaguchi et al., 2007 , Hyong et al., 2008 which contributes to brain edema that can worsen post-operative neurological function (Ayer et al., 2012 
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